What the business is, and whether it's a good one at a fair price.
Operates two service lines for pharmaceutical clients: Contract Development and Manufacturing Organization (CDMO) and Contract Research Organization (CRO). The CDMO business generated ₹1,417 crore in FY26, up 33% year-on-year, while the CRO business generated ₹775 crore, up 24% year-on-year. Together they delivered ₹2,192.49 crore in revenue for FY26, a 29% rise over the prior year. EBITDA reached ₹661 crore at a 30.66% margin, with net profit of ₹348.91 crore. A front-loaded capex of ₹1,100-1,300 crore is planned for FY27 — versus ₹633 crore in FY26 — with 62% allocated to CDMO and 38% to CRO/capabilities, aimed at nearly doubling manufacturing capacity by FY27. The largest cost lines are employees at 31.2% of revenue and materials at 26.4%, followed by other operating expenses (14%) and depreciation (7.6%). Middle East geopolitical tensions have raised input and logistics costs, prompting customer discussions on cost revisions.
Measured from the filed financials, judged against its Pharmaceuticals peers · as of FY26 — not investment advice
How has the market priced it — with filings on the timeline?
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
How does it stack up on valuation, returns and growth?
Loading peers…
Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.
Loading financials…
Who owns it — and is the promoter stake clean?
Loading shareholding…
Sign up to see the full company file
Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.
Answered from SAI LIFE SCIENCES LIMITED's filed financials and exchange disclosures
SAI LIFE SCIENCES LIMITED is a Pharmaceuticals & Biotechnology company listed on NSE and BSE, trading under the symbol SAILIFE.
Yes. Over the trailing twelve months SAI LIFE SCIENCES LIMITED reported a net profit of ₹362 Cr on revenue of ₹2,250 Cr.
Not in the latest reported year — SAI LIFE SCIENCES LIMITED's dividend payout for FY26 was nil.
Effectively yes. Debt stands at 0.04× equity.
On trailing P/E, SAI LIFE SCIENCES LIMITED ranks 152 of 169 in Pharmaceuticals — cheaper than 10% of them, against an industry median of 28.9×. This is a position, not a valuation judgement.
On a typical session SAI LIFE SCIENCES LIMITED moves 1.28% — that is the median absolute close-to-close move across its last 269 trading days. Announcement days are routinely larger.
Every NSE and BSE filing by SAI LIFE SCIENCES LIMITED appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.
Figures are as last reported and may lag the latest filing. Not investment advice.
